{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-001913","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.052134+00:00","generated_at":"2026-05-16T08:27:45.436816+00:00","sec_items":["3.01","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Reviva gets Nasdaq extension to March 27, 2026 for minimum bid price rule compliance","bullets":["Nasdaq Panel granted exception through March 27, 2026 to regain compliance with $1.00 minimum bid price.","Company requested hearing after delisting determination on Nov 11, 2025; hearing held Jan 8, 2026.","To regain compliance, closing bid price must be at least $1.00 for 10 consecutive business days.","Company may implement reverse stock split if needed; warns split may not maintain price increase.","Risk of delisting remains if unable to meet deadline or other Nasdaq listing requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-001913","json":"https://secwatch.observer/filing/0001437749-26-001913.json","markdown":"https://secwatch.observer/filing/0001437749-26-001913.md","text":"https://secwatch.observer/filing/0001437749-26-001913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/rvph20260122_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T08:27:45.436816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9454559ae2cda0ec3b64e57c6e93413683146749","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq hearing update notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-055912","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-05-13T21:00:25+00:00","headline":"iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance","event_type":"other_material","sec_items":["1.01","3.01","3.02","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-055912","json":"https://secwatch.observer/filing/0001213900-26-055912.json","markdown":"https://secwatch.observer/filing/0001213900-26-055912.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/ea0290143-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm","comparable_excerpt":"minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum\nBid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm"}},{"accession":"0001493152-26-019078","ticker":"GNLN","company_name":"Greenlane Holdings, Inc.","filed_at":"2026-04-27T23:59:59+00:00","headline":"Greenlane regains Nasdaq compliance; BIC limits warrant conversion; board lock-up to April 2027","event_type":"other_material","sec_items":["3.01","7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-019078","json":"https://secwatch.observer/filing/0001493152-26-019078.json","markdown":"https://secwatch.observer/filing/0001493152-26-019078.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743745/000149315226019078/0001493152-26-019078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743745/000149315226019078/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm","comparable_excerpt":"March 25, 2026, Greenlane Holdings, Inc. (the “ Company ”) received a written notice\n(the “ Notice ”) from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“ Nasdaq ”)\nindicating that Nasdaq s","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1743745/000149315226019078/0001493152-26-019078-index.htm"}},{"accession":"0001213900-26-060662","ticker":"TNON","company_name":"Tenon Medical, Inc.","filed_at":"2026-05-22T21:15:15+00:00","headline":"Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060662","json":"https://secwatch.observer/filing/0001213900-26-060662.json","markdown":"https://secwatch.observer/filing/0001213900-26-060662.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/ea0291962-8k_tenon.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm","comparable_excerpt":"May 21, 2026, Tenon Medical, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying\nthe Company that it is no longer in compliance with the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm"}},{"accession":"0001213900-26-060267","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-05-22T01:40:52+00:00","headline":"AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K","event_type":"other_material","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060267","json":"https://secwatch.observer/filing/0001213900-26-060267.json","markdown":"https://secwatch.observer/filing/0001213900-26-060267.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/ea0291955-8k_allinfuture.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm","comparable_excerpt":"May 19, 2026, All In FutureTech Alliance,\nInc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”)\nfrom the Listing Qualifications Department (the “Staff”) of","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm"}},{"accession":"0001213900-26-058167","ticker":"SNYR","company_name":"Synergy CHC Corp.","filed_at":"2026-05-18T13:01:37+00:00","headline":"Synergy CHC receives Nasdaq delisting notice for bid price below $1.00","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-058167","json":"https://secwatch.observer/filing/0001213900-26-058167.json","markdown":"https://secwatch.observer/filing/0001213900-26-058167.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1562733/000121390026058167/0001213900-26-058167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1562733/000121390026058167/ea0291276-8k_synergy.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm","comparable_excerpt":"May 15, 2026, Synergy CHC Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of\nThe Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1562733/000121390026058167/0001213900-26-058167-index.htm"}},{"accession":"0001104659-26-057974","ticker":"HUMA","company_name":"Humacyte, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057974","json":"https://secwatch.observer/filing/0001104659-26-057974.json","markdown":"https://secwatch.observer/filing/0001104659-26-057974.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/0001104659-26-057974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/tm2614071d1_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm","comparable_excerpt":"May 4, 2026, Humacyte, Inc. (the “Company”)\nreceived a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification\nthat, for the 30 consecutive business days ended May 1, 2026, th","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/0001104659-26-057974-index.htm"}},{"accession":"0001213900-26-059270","ticker":"XXI","company_name":"Twenty One Capital, Inc.","filed_at":"2026-05-20T12:49:08+00:00","headline":"Tether International acquires SoftBank's stake in Twenty One Capital; board members resign","event_type":"other_material","sec_items":["1.02","3.01","5.02","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 8.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-059270","json":"https://secwatch.observer/filing/0001213900-26-059270.json","markdown":"https://secwatch.observer/filing/0001213900-26-059270.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/ea0291071-8k_twenty.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm","comparable_excerpt":"o independent directors, the minimum number required during the transition period\nfor compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm"}},{"accession":"0001437749-26-016538","ticker":"RVPH","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-05-13T12:03:45+00:00","headline":"Reviva Pharmaceuticals to be delisted from Nasdaq May 14, 2026; will trade on OTCQB","event_type":"other_material","sec_items":["3.01","8.01"],"materiality_score":1.0,"calibrated_materiality_score":1.0,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 8.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016538","json":"https://secwatch.observer/filing/0001437749-26-016538.json","markdown":"https://secwatch.observer/filing/0001437749-26-016538.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/0001437749-26-016538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/rvph20260512_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm","comparable_excerpt":"May 12, 2026 indicating that the Panel had determined to delist the Company’s common stock from Nasdaq. The Company’s common stock will be suspended from trading on Nasdaq as of the open of trading on May 14, 2026. Begin","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/0001437749-26-016538-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}